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Antidepressant-induced hippocampal neurogenesis (AHN) is hypothesized to contribute to
increases in hippocampal volume among major depressive disorder patients after long-term
treatment. Furthermore, rodent studies suggest AHNmay be the cellular mechanismmediating
the therapeutic benefits of antidepressants.Here,weperform the first investigationof genome-
wide expression changes associated with AHN in human cells. We identify gene expression
networks significantly activated during AHN, and we perform gene set analyses to probe the
molecular relationship between AHN, hippocampal volume, and antidepressant response. The
latter were achieved using genome-wide association summary data collected from 30,717
individuals as part of the ENIGMA Consortium (genetic predictors of hippocampal volume
dataset), and data collected from 1,222 major depressed patients as part of the NEWMEDS
Project (genetic predictors of response to antidepressants dataset). Our results showed that the
selective serotonin reuptake inhibitor, escitalopram evoked AHN in human cells; dose-
dependently increasing the differentiation of cells into neuroblasts, as well as increasing
gliogenesis. Activated genome-wide expression networks relate to axon and microtubule
formation, and ribosomal biogenesis. Gene set analysis revealed that gene expression changes
associatedwith AHNwere nominally enriched for genes predictive of hippocampal volume, but
not for genes predictive of therapeutic response.
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1 | INTRODUCTION
Neurogenesis is the process by which new neurons are formed from
differentiating neural progenitor cells in the brain (Götz & Huttner,
2005). It is a process critical for neurodevelopment in utero, infancy
and adolescence (Johnson, 2001). Unlike most brain regions, the
subgranular zone of the dentate gyrus within the hippocampus has a
pool of neural progenitor cells that continue to show neurogenic
activity throughout adulthood, across a number of species, including
humans (Eriksson et al., 1998). This gives rise to hippocampal neurons
possessing uniquely plastic properties, including a reduced threshold
for long term potentiation and the ability to form new synaptic
connections within existing mature neuronal architecture (Eriksson
et al., 1998). Notably, levels of neurogenesis are affected by
environmental factors (Lledo, Alonso, & Grubb, 2006). In rodent
studies, stress hormones, immuno-inflammatory activation, diet,
exercise and medications have been reported to impact upon the
rate of hippocampal neurogenesis; with subsequent effects on
learning, memory and the regulation of mood (Murphy, Dias, &
Thuret, 2014; Musaelyan et al., 2014; Potts & Lim, 2012; Praag,
Kempermann, & Gage, 1999; Praag et al., 2002; Schoenfeld & Gould,
2012; Strangl & Thuret, 2009).
Reductions in hippocampal volume are also found across a
number of psychiatric disorders, most notably among major
depressive disorder patients (Videbech & Ravnkilde, 2004).
Studies have revealed that antidepressants increase hippocampal
neurogenesis in non-human animal models, and more recently in
human hippocampal progenitor cells (Anacker et al., 2011; Berton
& Nestler, 2006). Antidepressant-induced hippocampal neuro-
genesis (AHN) has been suggested as one important cellular
mechanism contributing to an increase in hippocampal volume
after long-term treatment (Malykhin, Carter, Seres, & Coupland,
2010). However, due to the inaccessible nature of hippocampal
progenitor cells in patients, there has been no conclusive evidence
directly supporting this relationship in humans. Furthermore, based
on convincing non-human animal data, AHN has been implicated as
a cellular mechanism governing antidepressant action (Santarelli
et al., 2003) but this, to our knowledge, has yet to be demonstrated
in humans.
Using a multidisciplinary approach accessing human hippo-
campal stem cells and leveraging large cohort datasets, the current
study attempted to extend our understanding in the field by
addressing two aims. First, we aimed to characterize genome-wide
expression networks activated during early AHN in human cells
treated with the selective serotonin reuptake inhibitor (SSRI),
escitalopram. Secondly, based on our expression results we aimed
to identify a gene set associated with AHN. We then tested
whether this gene set showed associative enrichment within
genome-wide association studies relating to: (i) hippocampal
volume, and (ii) antidepressant response. A significant enrichment
would suggest that AHN was activating pathways relevant to each
phenotype, and may represent the cellular mechanism contributing
to each phenotype.
2 | METHODS
2.1 | The hippocampal progenitor cell line
The multipotent, human hippocampal progenitor cell line HPC0A07/
03C (provided by ReNeuron, Surrey, UK) was used for all experiments,
as described previously (Anacker et al., 2011). ReNeuron’s HPC0A07/
03C cells were obtained from a 12-week-old fetus and immortalized
with c-mycER technology. In the presence of growth factors (FGF2
and EGF) and 4-OHT, progenitors cells will proliferate indefinitely.
Removal of these growth factors induces differentiation of cells into
hippocampal neurons, astrocytes, and oligodendrocytes, but not into
other cell types outside of the brain. Cells were grown in Dulbecco’s
Modified Eagle’s Media/F12 (DMEM:F12, Invitrogen, Paisley, UK)
supplemented with 0.03% human albumin (Baxter Healthcare,
Compton, UK), 100 μg/ml human apo-transferrin (Sigma, St-Louis,
MO), 16.2 μg/ml human putrescine DiHCl (Sigma), 5 μg/ml human
insulin (Sigma), 60 ng/ml progesterone (Sigma), 2 mM L-glutamine
(Sigma) and 40 ng/ml sodium selenite (Sigma). To maintain prolifera-
tion, 10 ng/ml human bFGF (Pepro Tech EC Ltd, London, UK),
20 ng/ml human EGF (Pepro Tech EC Ltd.) and 100 nM 4-OHT (Sigma)
were added in proliferating media and removed in differentiating
media. The cell line underwent routine checking for mycoplasma
contamination every 6 weeks. All cells were grown at 37°C, 5% CO2,
and in a humidified atmosphere.Within these sets of experiments each
“biological replicate” represents a subculture of cells obtained from a
different passage.
2.2 | Drug dose
The active metabolite of the SSRI escitalopram, (S)-citalopram, has a
therapeutic window of between 50 and 130 ng/ml (Kumar, Kung, &
Shinozaki, 2014), which corresponds to doses of between 120 and
313 nM in vitro. Subsequently, cells were treated with a range of
doses, incorporating this therapeutically-relevant window. Drug doses
were achieved by dissolving escitalopram oxalate (Sigma) in molecular
grade ethanol (Sigma) to form a 10mM stock solution. Drug doses
(145 nM, 290 nM, and 1160 nM) were then formed by dilution of the
stockwithmedia; with the relative proportion of ethanol kept constant
across all dose groups including a vehicle control (0 nM).
2.3 | Culture protocol
Our cell culture protocol was adapted from one described previously,
in which hippocampal neurogenesis was observed when cells were
treated with an SSRI during both the proliferative growth stage and
during the cell differentiation stage (Anacker et al., 2011). However,
we shortened this protocol from a 10-day drug treatment protocol to
9 days, in order to capture very early changes in neurogenesis.
Cells were seeded for 24 hr on laminin-coated 96 well (immuno-
cytochemistry experiments) or six well (gene expression experiments)
plates (Nunclon, Roskilde, Denmark). After seeding, cells were treated
with proliferating media containing varying doses of escitalopram
oxalate for 48 hr. At the end of the 48-hr drug treatment period,
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proliferating media was aspirated. Media was then replaced with
differentiating media (lacking EGF, bFGF, 4-OHT) twice over 1 hr to
ensure thorough removal of growth factors. Subsequently, this media
was replaced with differentiating media containing corresponding
doses of escitalopram, as in the proliferation protocol. The cells were
grown in differentiating media for 7 days during which they
differentiated into doublecortin and Map-2 positive neurons (See
Supplementary Information). Subsequently, cells underwent fixing
(96-well plates) and RNA collection (6-well plates). 96-well plates were
fixed in 4% paraformaldehyde for 20min at room temperature, and
then stored in phosphate buffered saline at 4°C for later immunocy-
tochemistry experiments. For cells grown in 6-well plates, media was
aspirated and 1ml of Trireagent (Sigma) was added for later RNA
isolation.
2.4 | Immunocytochemistry
For Immunocytochemistry experiments, three biological replicates
and three technical replicates were utilized for each staining condition,
n = 12 in total per staining condition; which is comparable to other
studies identifying moderate to large effect sizes using this cell line
(Anacker et al., 2011). The primary outcomemeasures of interest were
changes to Doublecortin (Dcx) staining, that is, the differentiation of
progenitor cells into to neuroblasts, and Map-2, that is, a marker for
more mature neurons. However, we also assessed other markers
assaying proliferation, using BrdU and Ki67 staining; changes to
gliogenesis using S100β staining; and cell death, using cleaved
caspase-3 (CC3) staining. For more details, see S1 and S2.
2.5 | Transcriptomics
RNA from cell experiments was isolated using Trireagent (Sigma)
following the standard protocol, with an additional ethanol precipita-
tion step to increase RNA purity. For gene expression experiments we
utilized six biological replicates at four drug doses (n = 24 total). RNA
samples were processed on Illumina Human HT-12 v4 Expression
BeadChip (Illumina Inc., San Diego, CA) according to manufacturer’s
protocol. For more details, see S3.
2.6 | Statistical analysis
2.6.1 | Immunocytochemistry experiments
For each biological replicate, percentage change in marker immuno-
fluorescence from our drug treated cells relative to controls was
calculated for each technical triplicate and the mean was taken. Linear
regressions were then used to assess the relationship between
percentage change in marker immunofluorescence and: (i) drug/no
drug (dose groups collapsed), and (ii) drug dose, whilst co-varying for
staining batch. Within each of the four staining groups targeting
different biological questions (differentiation: Dcx, Map-2; prolifera-
tion: BrdU, Ki67; gliogenesis: S100β; cell death: CC3) we applied a
Bonferroni correction for the number of tests. We consider corrected
P values of P ≤ 0.05 as significant. See Supplementary Materials for
more information.
2.6.2 | Transcriptomic experiments
Probes were normalized using a systematic approach incorporating
the Lumi package (Du, Kibbe, & Lin, 2008) and analyzed using R (www.
r-project.org). Probes were filtered to remove lowly detected probes
and to investigate only the 7,500 most variable probes, see
Supplementary Materials. For transcriptomic studies we focused on
the dose-dependent effects of drugs on gene expression only. A linear
regression was performed, where probe expression was selected as
the dependent variable, dose as the independent variable, and batch
and biological replicate included as factors. A total sample number of
24 provided 80% power to detect a 1.5 fold change in expression as
part of a two-tailed t-test at a level of significance corrected for
multiple comparisons (pcorr = 0.05/7500 = P ≤ 6.6E-6), with an esti-
mated standard deviation of 0.5. For more details, see S4.
2.6.3 | Gene network analysis
To understand which biological mechanisms may be affected by drug
dose, in a hypothesis-free manner, we used Webgestalt (bioinfo.
vanderbilt.edu/webgestalt/). All probes nominally predicted by
drug dose (P ≤ 0.05) were tested for Gene Ontology (version 1.2)
term enrichment with Biological Processes (GOTERM_BP_FAT),
Cellular Components (GOTERM_CC_FAT), Molecular Function
(GOTERM_MF_FAT) and KEGG pathways. We utilized all probes
surviving background correction as our comparison group or
“background list.”We further entered geneswithin enriched pathways
of interest into Gene Mania (http://www.genemania.org), in order to
visualize gene expression networks.
2.6.4 | Genetic pathway analysis
We identified a gene set by selecting all genes showing nominally
significant expression changes (P ≤ 0.05) in our data set, and we tested
if our gene set was enriched for associative signal with two
phenotypes: (i) hippocampal volume in adults; (ii) antidepressant
response. We achieved this using the pathway analysis tool, MAGMA
(Leeuw, Mooij, Heskes, & Posthuma, 2015), with a 35 kb 5′ and 10 kb
3′window around genes and the results from two large genome-wide
association studies (GWAS). There were genome-wide summary
statistic data from the ENIGMAConsortium, which performed ameta-
analysis identifying the genetic predictors of hippocampal volume in a
total of 30,717 subjects (http://enigma.ini.usc.edu) (Hibar et al., 2015)
and results from the NEWMEDS project, which has investigated
genetic predictors of antidepressant response (Tansey et al., 2012).
Within NEWMEDSwe utilize the GWAS results specifically relating to
SSRIs, which is derived from a total of 1,222major depressive disorder
patients (Tansey et al., 2012). Antidepressant response was defined as
an adjusted continuous measure capturing change in depression
severity after taking an SSRI for a number of weeks (see Tansey et al.
(2012), for more details).
MAGMA tests for gene set enrichment by first generating a gene-
wide statistic from the GWAS results files, adjusting for gene size, SNP
density and linkage disequilibrium effects (Leeuw et al., 2015).
MAGMA then performs a competitive test of gene set association
to investigate if associative enrichment within a user-defined gene set,
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outperforms other gene sets from across the genome of similar size
(Leeuw et al., 2015). Due to the stringent nature of the competitive
test within MAGMA, the fact that the two phenotypes under
investigation relate to two separate biological questions, and the
fact the genome-wide datasets consist of vastly different sample sizes,
we considered a P-value threshold of P ≤ 0.05 as significant.
3 | RESULTS
3.1 | Immunocytochemistry
3.1.1 | Effects of escitalopram on neuronal differentiation
Doublecortin staining was used to measure early changes in the
differentiation of progenitor cells into immature neurons (neuroblasts)
andMap-2was used tomeasure changes in the differentiation ofmore
mature neurons. Results revealed a dose-dependent increase in the
differentiation of cells into neuroblasts as characterized by the marker
doublecortin (F = 15.014, d.f. = 1, P = 0.006), see Figure 1. This effect
remained significant after multiple testing correction (4 tests;
corrected P = 0.024). There were no other significant changes
(P > 0.05).
3.1.2 | Effects of escitalopram on other cell markers
BrdU and Ki67 were used to assess changes in proliferation. Our
staining also revealed significant increases in BrdU staining in cells
(independent of dose) treated with escitalopram (F = 9.358, d.f. = 1,
P = 0.018), but this effect was not significant after multiple testing
correction (4 tests; corrected P > 0.05).
S100β was used to assess gliogenesis. We found increases in
S100β in cells treated with escitalopram, independent of dose
(F = 28.813, d.f. = 1, P = 0.001), which remained significant after
multiple testing correction (2 tests; corrected P = 0.002).
CC3 staining confirmed that the drug/drug doses were not
inducing cell death (uncorrected P > 0.05). See Supplementary
Information for more details.
3.2 | Transcriptomics
Our results revealed one genome-wide significant expression change
in the Nucleolar protein 6 (NOL6) gene (Probe: ILMN_7349, t = 6.485,
FIGURE 1 Top: Bar chart shows that the mean percentage of cells expressing doublecortin dose-dependently increases relative to control
conditions in differentiating cells treated with escitalopram, based on linear regressions, covarying for staining batch (P ≤ 0.01, n = 12). Error
bars represent the standard error of the mean. Bottom: Corresponding images of cell nuclei (blue) and marker immunofluorescence (green) in
differentiating cells treated with escitalopram at each drug dose. [Color figure can be viewed at wileyonlinelibrary.com]
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S.E. = 3.376e-05, P = 5.600e-06), which showed a dose-dependent
increase in expression, see S8.
3.3 | Gene ontology and KEGG pathway analysis
545 probes were nominally associated with drug dose (P < 0.05) and
were input into Webgestalt. There were a total of 13 Bonferonni
corrected GO terms associated with drug dose, see Table 1. Results
fromKEGGpathway analysis identified anenrichment in the “Ribosome
biogenesis in eukaryotes” pathway (Enrichment Ratio = 5.28; Corrected
P = 0.0045; Figure 2).
3.4 | AHN gene set and its relationship to
hippocampal volume and antidepressant response
545 probes were nominally associated with drug dose (P < 0.05) and
MAGMA tested for enrichment of this gene setwithinGWASdatasets.
In our first analysis, we found a nominally significant enrichment of our
AHN gene set in GWAS results relating to hippocampal volume
(competitive P = 0.031). However, the AHN gene set did not show a
significant enrichment within the antidepressant response GWAS data
(competitive P = 0.464).
4 | DISCUSSION
Our results show that escitalopram dose-dependently accelerated the
differentiation of human hippocampal progenitor cells into neuro-
blasts, Figure 1, whilst also increasing gliogenesis. Our findings in
human cells are supported by rodent studies, which have shown that
escitalopram treatment correlates with increases in hippocampal
cytogenesis (Jayatissa, Bisgaard, Tingström, Papp, & Wiborg, 2006).
Our immunocytochemistry data are also complemented by our
corresponding gene expression data, which revealed “Axon” and
“Microtubule” as two significant GO terms with the highest enrich-
ment ratios, Table 1.Within these networks, the transcripts of gamma-
aminobutyric acid B receptor, 1 (GABBR1) andMicrotubule-associated
protein 1B (MAP1B) act as hub genes, suggesting they may represent
important drug targets, Figure 2. Indeed, the reduction in GABBR1
expression found in our study is corroborated by other reports
showing that a reduction in GABA receptor binding stimulates
neurogenesis (Giachino et al., 2014). In contrast, MAP1B shows an
increase in expression in response to escitalopram dose. MAP1B is a
protein involved in microtubule assembly; a process essential for
mediating neurogenesis (Beermann & Shea, 1994).
The KEGG pathway analysis revealed that “Ribosome biogenesis
in eukaryotes” was also an enriched pathway, and features Nucleolar
protein 6 (NOL6) as a hub gene; the transcript most significantly
affected by escitalopram dose, showing a dose-dependent increase in
expression, Figure 2. Ribosomal biogenesis involves the synthesis of
the machinery involved in polypeptide formation, and subsequently
determines the translational capacity of a cell (Bernstein, Gallagher,
Mitchell, Granneman, & Baserga, 2004). Our findings corroborate
previous studies implicating increases in ribosomal biogenesis in cells
undergoing increases in proliferation, neurite formation and synapto-
genesis (Hsieh, 2012).
In our hypothesis-driven genetic pathway analysis, we found that
our AHN gene set was nominally enriched for genes predicting
hippocampal volume in adults. This suggest that increases in
hippocampal volume observed after long-term antidepressant treat-
ment are likely mediated through the activation of neurogenic
pathways, as opposed to solely a reduction in neuronal cell death.
However, our AHN gene set was not enriched for genes predictive of
antidepressant response, suggesting that in contrast to non-human
animal findings (Santarelli et al., 2003), AHN may not be the cellular
mechanism governing therapeutic response to SSRIs in humans. There
are, however, a number of alternative interpretations to this finding.
For example, rather than a direct causal link between AHN and
TABLE 1 Gene Ontology (GO) terms significantly enriched in gene expression data generated while differentiating hippocampal progenitor cells
are treated with escitalopram, sorted by enrichment ratio
Database GO name GO ID Enrichment ratio Corrected P-value
Cellular component Axon GO:0030424 2.94 0.0028
Cellular component Microtubule GO:0005874 2.57 0.0164
Molecular function RNA binding GO:0003723 1.88 0.0382
Cellular component Mitochondrion GO:0005739 1.66 0.0153
Cellular component Cytoplasm GO:0005737 1.23 2.39E-05
Cellular component Cytoplasmic part GO:0044444 1.22 0.0328
Molecular function Protein binding GO:0005515 1.19 0.0382
Cellular component Intracellular membrane-bounded organelle GO:0043231 1.16 0.0328
Cellular component Intracellular GO:0044424 1.15 6.61E-05
Cellular component Intracellular organelle GO:0043229 1.15 0.008
Cellular component Organelle GO:0043226 1.15 0.0094
Cellular component Intracellular GO:0005622 1.14 6.15E-05
Molecular function Binding GO:0005488 1.09 0.0382
Data were generated by inputting 545 probes nominally associated with drug dose (P < 0.05) into Webgestalt.
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antidepressant response, AHN might simply facilitate therapeutic
response through increasing “plasticity” allowing social support
networks and positive, enriching environmental factors to have an
enduring effect on the brain and mood of patients (Spalding et al.,
2013). Indeed, non-human studies have shown that enriched environ-
ments (e.g., increases in running) can moderate hippocampal neuro-
genesis and evoke antidepressant effects (Spalding et al., 2013; van
Praag, Kempermann, & Gage, 1999). Consequently, the heteroge-
neous environments experienced by patients outside of the clinic may
moderate the impact of AHN on therapeutic response, preventing us
from identifying a direct genetic relationship.
Although our findings are promising, this study has several
limitations. First of all, an in vitro model cannot fully account for the
milieu of environmental factors present in human major depressive
disorder patients (hormones, diet, levels of physical activity), which can
moderate hippocampal neurogenesis. Secondly, the human hippocam-
pal progenitor cell line used is fetal in origin and results obtained from
this study may not reflect how adult cells respond to antidepressants.
Thirdly, the differentiation protocol utilized here was relatively short,
which allowed us to characterize very early AHN, asmarked by changes
to doublecortin but not Map-2. Future studies could also investigate
gene expression changes caused by escitalopram during neuronal
maturation using a longer protocol. Fourth, our ability to detect
enrichment of our AHN gene set for genes relating to hippocampal
volume (ENIGMA study) but not antidepressant response (NEWMEDS
study)may relate topower.For instance, theENIGMAsampleutilizedan
FIGURE 2 Top Left: Gene expression networks activated whilst differentiating cells are treated with varying doses of escitalopram. These
figures show transcripts from our experimental data (black) and predicted transcripts (grey) involved in three pathways which show
enrichment in our data: (i) Axon (GO:0030424), top left; (ii) Microtubule (GO:0005874), top right; and (iii) Ribosomal Biogenesis (KEGG
Pathway), bottom. Genes with an adjacent green arrow represent those showing an increase in expression in response to escitalopram dose,
genes marked with a red arrow represent those showing a decrease in expression. [Color figure can be viewed at wileyonlinelibrary.com]
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objective phenotype (hippocampal volume) and a large sample size
(n = 30,717), giving it excellent power to detect genetic predictors. In
contrast, the NEWMEDS sample suffers from the fact it measures a
more subjective and heterogeneous phenotype (antidepressant re-
sponse) in a sample size (n = 1,222) over twenty times smaller than the
ENIGMA cohort. Consequently, in order to draw firmer conclusions
regarding the relationship between AHN and antidepressant response,
a larger patient sample size is needed in future studies.
Despite these limitations, this study is the first to: (i) find that
escitalopram increases neurogenesis in human hippocampal progeni-
tor cells; (ii) identify gene expression networks activated during AHN;
(iii) use genetic pathway analysis to reveal that AHN gene expression
changes are nominally enriched for genes predictive of adult
hippocampal volume, but not genes for antidepressant response.
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